A recent report indicates that proposed tariffs on pharmaceuticals could raise annual drug costs in the United States by as much as $51 billion. The ongoing trade tensions, particularly with China, are expected to have a severe impact on the healthcare sector, potentially leading to drug shortages and increased prices for consumers. Industry executives warn that tariffs may negatively affect the availability of lower-cost generic medications, posing a risk to patients who rely on affordable prescriptions. The U.S. Commerce Department has initiated investigations into the effects of these tariffs, which could have broader implications for both pharmaceutical and semiconductor sectors. Experts and lawmakers are expressing concern over the political and economic ramifications of these tariff policies, particularly under the current administration.